Everything below concerns WADA Prohibited List. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
February 27, 2009: Finland Statistics Finland informs that Finland's gross domestic product diminished by 1.3% in the last quarter of 2008 from the previous quarter. The growth slowed down already in early 2008 and in the third quarter output diminished by 0.3% from the previous quarter.
Multiple sclerosis (MS) is a chronic and neurodegenerative autoimmune disease in which the immune system attacks myelin, the insulating cover of nerve cells, causing damage to the central nervous system. This impairs the nervous system's ability to transmit signals. Symptoms include double vision, vision loss, eye pain, muscle weakness, loss of coordination, as well as cognitive issues like problems with memory. MS may be a rare complication of an Epstein-Barr virus (EBV) infection. Genetics and environmental factors like exposure to sunlight also impact the risk of MS. MS can be diagnosed based on symptoms, MRI scans, and sometimes a lumbar puncture to investigate spinal fluid. There is no cure for MS. Current treatments aim to manage symptoms during acute flares and prevent further attacks with disease-modifying therapies. With effective treatment, it is possible to reduce attacks strongly, but the disease progress is not fully stopped. In addition, symptoms of MS like balance issues can be managed with drugs and with non-drug treatments (e.g. physical therapy). On average, life expectancy is slightly lower than normal. In 2024, about 3.1 million people were affected by MS globally, with rates much higher further from the equator. The disease usually begins between the ages of 20 and 40 and is almost three times more common in women than in men. MS was first described in 1868 by French neurologist Jean-Martin Charcot.
=== N05BA Benzodiazepine derivatives === N05BA01 Diazepam N05BA02 Chlordiazepoxide N05BA03 Medazepam N05BA04 Oxazepam N05BA05 Dipotassium clorazepate N05BA06 Lorazepam N05BA07 Adinazolam N05BA08 Bromazepam N05BA09 Clobazam N05BA10 Ketazolam N05BA11 Prazepam N05BA12 Alprazolam N05BA13 Halazepam N05BA14 Pinazepam N05BA15 Camazepam N05BA16 Nordazepam N05BA17 Fludiazepam N05BA18 Ethyl loflazepate N05BA19 Etizolam N05BA21 Clotiazepam N05BA22 Cloxazolam N05BA23 Tofisopam N05BA24 Bentazepam N05BA25 Mexazolam N05BA26 Oxazolam N05BA27 Metaclazepam N05BA56 Lorazepam, combinations
Sources: en.wikipedia.org
== Further reading == Castka, Joseph F.; Metcalfe, H. Clark; Davis, Raymond E.; Williams, John E. (2002). Modern Chemistry. Holt, Rinehart and Winston. ISBN 978-0-03-056537-3. Guch, Ian (2003). The Complete Idiot's Guide to Chemistry. Alpha, Penguin Group Inc. ISBN 978-1-59257-101-7. Mascetta, Joseph A. (1998). How to Prepare for the SAT II Chemistry. Barron's. ISBN 978-0-7641-0331-5.
== β-Lipotropin == β-Lipotropin is a 90-amino acid polypeptide that is the carboxy-terminal fragment of POMC. It was initially reported to stimulate melanocytes to produce melanin. It was also reported to perform lipid-mobilizing functions such as lipolysis and steroidogenesis. However, no subsequent studies have been published that support these early findings and no receptor has been identified for β-lipotropin. β-Lipotropin can be cleaved into smaller peptides. In humans, γ-lipotropin, β-MSH, and β-endorphin, are all possible fragments of β-lipotropin. β-endorphin is the predominant opioid of the anterior human and rat pituitary gland. Birdsall and Hulme demonstrated that the C-fragment of lipotropin (β-endorphin) has a high affinity for opiate receptors in the brain, and the binding was reversed by naloxone, a classical antagonist of the opiates (Bradbury et al. 1976a). Alongside this, Feldberg found that β-endorphin administered in cat ventricles was 100 times more potent than morphine as an analgesic agent (Feldberg & Smyth 1976, 1977) and the analgesia persisted for several hours. Feldberg concluded that β-endorphin was the most potent analgesic agent known. β-Lipotropin is found in essentially equimolar concentrations to that of corticotropin. Evidence shows that β-Lipotropin is metabolized into endorphins that can greatly affect mood and behavior and is thus regarded as a prohormone.
=== Bioactive molecule layer === Finally, the bioactive molecule of interest is loaded into the carbohydrate layer. This process typically occurs through either lyophilization or passive adsorption, and the fully functionalized aquasome is then characterized.
== Habitat and ecology == Rhizopus oryzae can be found in various soils across the world. For example, it has been found in India, Pakistan, New Guinea, Taiwan, Central America, Peru, Argentina, Namibia, South Africa, Iraq, Somalia, Egypt, Libya, Tunisia, Israel, Turkey, Spain, Italy, Hungary, Czech Republic, Slovakia, Germany, Ukraine, British Isles, and the USA. The soils where R. oryzae has been isolated are varied ranging from grassland, cultivated soils under lupin, corn, wheat, groundnuts, other legumes, sugar canes, rice, citrus plantations, steppe type vegetation, alkaline soils, salt-marshes, farm manure soils, to sewage filled soils. The pH of the soils where the species has been isolated typically range from 6.3 to 7.2. Rhizopus oryzae is often identified as R. arrhizus when isolated from foods. It is found in rotting fruits and vegetables where it is often called R. stolonifer. Unlike the other species such as R. stolonifer, R. oryzae is common in tropical conditions. In East Asia, it is common in peanuts. For instance, there was 21% isolation from peanut kernels from Indonesia. It is present in maize, beans, sorghum, and cowpeas, pecans, hazelnuts, pistachios, wheat, barley, potatoes, sapodillas, and various other tropical foods. Maize meal on which isolates of R. oryzae had been grown was found to be toxic to ducklings and rats, causing growth depression.
Sources: en.wikipedia.org
Amid a surge in inflation and high gas prices, Biden's approval ratings declined, with his disapproval rating surpassing his approval rating in early 2022. After 5.9% growth in 2021, real GDP growth cooled in 2022 to 2.1%, after slightly negative growth in the first half spurred recession concerns. Job creation and consumer spending remained strong, as the unemployment rate fell to match a 53-year low of 3.5% in December. Inflation peaked at 9.1% in June before easing to 3.2% by October 2023. Stocks had had their worst year since 2008 before recovering. Widespread predictions of an imminent recession did not materialize in 2022 or 2023, and by late 2023 indicators showed sharply lower inflation with economic acceleration. GDP growth hit 4.9% in the third quarter of 2023 and the year ended with stocks near record highs, with robust holiday spending. Biden signed numerous major pieces of economic legislation in the 117th Congress, including the American Rescue Plan, Infrastructure Investment and Jobs Act, CHIPS and Science Act, and the Inflation Reduction Act. He signed the CHIPS and Science Act into law on August 9, 2022. It provided billions of dollars in new funding to boost domestic research on and manufacture of semiconductors, to compete economically with China. In his third month in office, Biden also signed an executive order to increase the minimum wage for federal contractors to $15 per hour. The order went into effect for 390,000 workers in January 2022. His administration rigorously enforced antitrust law.
==== Eva Kaili ==== Kaili denied any wrongdoing in the controversy. Her lawyers appeared on Greek TV stating that she "declares her innocence and that she has nothing to do with bribery from Qatar". Kaili's lawyers were also critical of her arrest as a "gross overreach of judicial power". They maintain that Kaili was in a state of shock, fear and confusion during her first interview and that she was not provided with an interpreter for the interview. According to her lawyers, it took a week for Kaili to be in "good enough psychological condition to be fully aware of what she was saying". Kaili reportedly felt "very troubled" and betrayed by her partner, Giorgi, according to her lawyers. Kaili has accused the Belgian authorities of "inhuman" behavior due to the Belgian authorities refusal to allow her to see her daughter in person or via Skype. Kaili said: "I am being tortured, this is so unfair that I cannot stand it, and I am breaking down. What is the problem with my little girl, why are they keeping her away from me?". The following day a three-hour meeting between Kaili and her daughter was authorised. The court decided on 16 February 2023 to keep Kaili in detention for another two months. Kaili had changed her Belgian lawyer from André Risopoulo to Sven Mary some time before the hearing. Mary had "represented one of the terrorists behind the 2015 Paris attacks". Kaili was released from pre-trial detention with an electronic bracelet on 14 April 2023 and, throughout the process, has continued to deny all charges against her.
=== Lymphangiology === An improved understanding of mesenteric structure and histology has enabled a formal characterization of mesenteric lymphangiology. Stereologic assessments of the lymphatic vessels demonstrate a rich lymphatic network embedded within the mesenteric connective tissue lattice. On average, vessels occur every 0.14 mm (0.0055 in), and within 0.1 mm (0.0039 in) from the mesocolic surfaces—anterior and posterior. Lymphatic channels have also been identified in Toldt's fascia, though the significance of this is unknown.
In March 2018 Sara Rojas and her team published their research on drug incorporation and delivery with various biocompatible MOFs other than CD-MOF-1 through simulated cutaneous administration. The group studied the loading and release of ibuprofen (hydrophobic) and aspirin (hydrophilic) in three biocompatible MOFs (MIL-100(Fe), UiO-66(Zr), and MIL-127(Fe)). Under simulated cutaneous conditions (aqueous media at 37 °C) the six different combinations of drug-loaded MOFs fulfilled "the requirements to be used as topical drug delivery systems, such as released payload between 1 and 7 days" and delivering a therapeutic concentration of the drug of choice without causing unwanted side effects. The group discovered that the drug uptake is "governed by the hydrophilic/hydrophobic balance between cargo and matrix" and "the accessibility of the drug through the framework". The "controlled release under cutaneous conditions follows different kinetics profiles depending on: (i) the structure of the framework, with either a fast delivery from the open structure MIL-100 or a slower drug release from the narrow 1D pore system of MIL-127 or (ii) the hydrophobic/hydrophilic nature of the cargo, with a fast (Aspirin) and slow (Ibuprofen) release from the UiO-66 matrix." Moreover, a simple ball milling technique is used to efficiently encapsulate the model drugs 5-fluorouracil, caffeine, para-aminobenzoic acid, and benzocaine. Both computational and experimental studies confirm the suitability of [Zn4O(dmcapz)3] to incorporate high loadings of the studied bioactive molecules.
In 1965, Francisco Condom was elected Grand Master. Leadership stabilized, but membership fell. From 1959 to 1980, membership in Freemasonry in Cuba declined by 40% in a period of sharp and intense reduction. Where in 1959, there were over 34,000 Freemasons, in 1980, that number had fallen to below 20,000. US narratives attributed this decline to a mistrust that the Communist regime held of Freemasonry, Cuban narratives attributed this to the economic impact that the Revolution had on the upper and middle classes, which had previously been the bulk of Freemasons in Cuba, and the former barriers to entry that existed for those in the working class. Cuba's most prominent economic trading partners were the Soviet Union and the Eastern Bloc coalition, where Freemasonry had been entirely outlawed since the time of the Bolsheviks. Castro desired to maintain positive relations with Cuba's primary economic benefactors, and to avoid a political scandal, he did not see any use of Freemasonry as a tool in Cuba's foreign policy. Additionally, in those impoverished countries where Cuba desired to spread its brand of Marxism, Freemasonry had long been seen as a gentlemen's club for colonizers. Castro therefore limited international travel for Freemasons. From 1960 to 1980, due to a negative societal stereotype about the working character of Freemasonry, if Freemasons were discovered, they struggled to maintain positions at university and trade schools, secure employment, or be promoted at work. On March 28, 1965, Francisco M.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.